Solid Dosage
GEA provides proven solutions for manufacturing even the most challenging dosage forms of cardiovascular medication.
There are many types and combinations of medicines available to treat coronary heart disease (CHD), high blood pressure or heart failure, including anticoagulants, antiplatelet medications, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta blockers, calcium channel blockers, digoxin and diuretics.
Whatever the active ingredient, GEA provides proven solutions for even the most challenging dosage forms, such as MUPS tablets, effervescents and multi-layer dosage forms, as well as granules, pellets, modified/extended release formulations, powders designed for direct tableting or capsule filling and high-volume applications.
Still an important unit operation, coating is used to either add color, protect, mask the taste or create a modified release form in pharmaceutical production. GEA offers a range of standard, innovative, batch and continuous coater systems
Plus, as containment experts, the company offers the largest selection of solutions for contained processing based on a thorough containment risk analysis.
Providing increased yields, lower utility consumption and reduced waste, continuous manufacturing presents a new approach to high-volume oral dosage form production and meets the industry’s demands for faster product development, reduced costs, improved production economics and increased manufacturing flexibility.
Showing 4 of 27
Combining process monitoring using online analyzers, together with solid process engineering principles and advanced process modelling techniques will enable processes to be actively controlled in order to compensate for input variations.
Innovative CIP concepts of GEA meet comprehensive high standards. Our experts guarantee product safety at every point of the process. Every upgrade is adapted to individual local conditions and customer requirements and leads to noticeable savings.
Contained Materials Handling solutions for Primary and Secondary Pharmaceuticals and Healthcare. With extensive experience within the generics sector, supply a wide range of technologies and equipment that improve and enhance the efficiency and performance of Oral Solid Dosage production.
The ConsiGma® DC for direct compression is the latest expansion of GEA's continuous portfolio for cost effective, compact, high yield manufacturing systems. It offers a robust and flexible manufacturing method for a wide range of products.
Companies like GEA process and store large amounts of sensitive data. However, security incidents, from ransomware attacks to physical intrusions and industrial espionage, are ever-expanding. GEA’s effective protection of its business partners’ data – as well as its own proprietary information – is evolving into a competitive advantage. We spoke with Iskro Mollov, GEA’s Chief Information Security Officer, about what it takes to protect a global business in a volatile world.
Resource-efficient fashion has been a long-sought ambition amid the fashion industry’s considerable contributions to global carbon emissions. The need to close the loop by recycling textile fibers into virgin-like materials is higher than ever but seemed like a distant dream until now: Circ, GEA’s American customer and pioneer in the field of textile recycling, might be rewriting the future of the fashion industry.
Alternative proteins are promising – yet still expensive to produce. The usual response is that scaling up will solve this issue. But what if the solution was really about getting better, not just bigger? From more efficient, high-yield processes to upcycling waste heat, engineers are reshaping how we grow food.